Pharma Bavaria International GmbH

Pharma Bavaria International is a global reach company that distributes and promotes high-quality pharmaceuticals with well-researched ingredients. In line with our vision - Access to Quality Healthcare - we offer a vast portfolio of prescription’s medicines that includes different therapeutic options for different pathologies, plus Pharma Bavaria International has LAB BOTANIC BAVARIA, an umbrella that covers OTCs and a range of herbal/supplement products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

NANOPASS AND M2N ENTER STRATEGIC DEVELOPMENT & FOUNDRY AGREEMENT

NanoPass; M2N | December 23, 2021

news image

NanoPass Technologies and Micro2Nano have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles. The aim of the collaboration is to strengthen the relationship between NanoPass and M2N and provide a basis for the continued growth of the two comaim of the collaboration is to strengthen the relationship between NanoPass and M2N panies while basing the new agreement on year...

Read More

BUSINESS INSIGHTS

ENCLARA PHARMACIA EARNS FIVE YEAR CONTRACT EXTENSION WITH VITAS HEALTHCARE

Enclara Pharmacia | February 18, 2022

news image

Enclara Pharmacia the market leader in comprehensive pharmacy benefits management (PBM) services to the hospice community, has announced a five-year contract extension to continue providing comprehensive patient medication management services to VITAS Healthcare, the nation’s leading provider of hospice and palliative care. The contract extension affirms the longstanding collaboration between the two companies based on excellence, innovation and quality care for hospice patients and their ...

Read More

OSTRICH PHARMA USA PRODUCES ANTIBODIES TO BLOCK THE VIRUS THAT CAUSES COVID-19

Business Wire: | April 01, 2020

news image

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodie...

Read More

U.S. FDA ALLOWS PRIORITY REVIEW TO NEW DRUG APPLICATION FOR VERICIGUAT TREATING CHRONIC HEART FAILURE

Merck | July 17, 2020

news image

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with ...

Read More
news image

BUSINESS INSIGHTS

NANOPASS AND M2N ENTER STRATEGIC DEVELOPMENT & FOUNDRY AGREEMENT

NanoPass; M2N | December 23, 2021

NanoPass Technologies and Micro2Nano have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles. The aim of the collaboration is to strengthen the relationship between NanoPass and M2N and provide a basis for the continued growth of the two comaim of the collaboration is to strengthen the relationship between NanoPass and M2N panies while basing the new agreement on year...

Read More
news image

BUSINESS INSIGHTS

ENCLARA PHARMACIA EARNS FIVE YEAR CONTRACT EXTENSION WITH VITAS HEALTHCARE

Enclara Pharmacia | February 18, 2022

Enclara Pharmacia the market leader in comprehensive pharmacy benefits management (PBM) services to the hospice community, has announced a five-year contract extension to continue providing comprehensive patient medication management services to VITAS Healthcare, the nation’s leading provider of hospice and palliative care. The contract extension affirms the longstanding collaboration between the two companies based on excellence, innovation and quality care for hospice patients and their ...

Read More
news image

OSTRICH PHARMA USA PRODUCES ANTIBODIES TO BLOCK THE VIRUS THAT CAUSES COVID-19

Business Wire: | April 01, 2020

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodie...

Read More
news image

U.S. FDA ALLOWS PRIORITY REVIEW TO NEW DRUG APPLICATION FOR VERICIGUAT TREATING CHRONIC HEART FAILURE

Merck | July 17, 2020

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with ...

Read More